Compliance Rate
Compliance Rate
50.0%
Compliant submissions
1
Incompliant submissions
1
Total trials
2
My Organizations' Clinical Trials
Showing 225 of 3499 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/14/16
End: 04/15/20
Due: 04/15/21
Phase: N/A
Priority: Normal
Start: 11/30/08
End: 12/31/13
Due: 12/31/14
Phase: N/A
Priority: Normal
Start: 08/31/99
End: 08/31/04
Due: 08/31/05
Phase: N/A
Priority: Normal
Start: 09/30/04
End: -
Due: -
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
Phase: N/A
Priority: Normal
Start: 07/17/13
End: 11/30/18
Due: 11/30/19
Phase: N/A
Priority: Normal
Start: 07/07/17
End: 10/16/21
Due: 10/16/22
Phase: N/A
Priority: Normal
Start: 06/30/09
End: 03/31/10
Due: 03/31/11
Phase: N/A
Priority: Normal
Start: 01/31/08
End: 07/31/13
Due: 07/31/14
Phase: N/A
Priority: Normal
Start: 03/31/12
End: 10/31/12
Due: 10/31/13
Phase: N/A
Priority: Normal
Start: 01/23/12
End: 02/11/16
Due: 02/11/17
Phase: N/A
Priority: Normal
Start: 10/31/02
End: 09/30/13
Due: 09/30/14
Phase: N/A
Priority: Normal
Start: 08/08/19
End: 12/01/21
Due: 12/01/22
Phase: N/A
Priority: Normal
Start: 05/31/04
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 10/31/90
End: 08/31/03
Due: 08/31/04
Phase: N/A
Priority: Normal
Start: 09/30/06
End: 02/28/09
Due: 02/28/10
Phase: N/A
Priority: Normal
Start: 12/31/11
End: 07/31/14
Due: 07/31/15
Phase: N/A
Priority: Normal
Start: 04/26/13
End: 09/21/22
Due: 09/21/23
Phase: N/A
Priority: Normal
Start: 03/31/01
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 03/07/22
End: 03/30/25
Due: 03/30/26
Phase: N/A
Priority: Normal
Start: 08/31/96
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 08/12/13
End: 10/26/22
Due: 10/26/23
Phase: N/A
Priority: Normal
Start: 03/10/20
End: 11/30/20
Due: 11/30/21
Phase: N/A
Priority: Normal
Start: 08/31/02
End: 10/31/07
Due: 10/31/08
Phase: N/A
Priority: Normal
Start: 04/30/02
End: 07/31/09
Due: 07/31/10
Phase: N/A
Priority: Normal
Start: 06/14/17
End: 11/08/21
Due: 11/08/22